WHAT IS CLAIMED:

1. ~~A method of treating rhinitis comprising administering an effective amount of a~~A pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP)~~, to an animal in need thereof.~~ for use in the treatment of rhinitis.
2. The ~~method of C~~use as claimed in claim 1, wherein the rhinitis is allergic rhinitis.
3. The ~~method of C~~use as claimed in claim 1, wherein the effective amount of the DA-DKP in the composition is from ~~about~~ 100 µg to ~~about~~ 3000 µg per day.
4. The ~~method of C~~use as claimed in claim 1, wherein the effective amount of the DA-DKP in the composition is from about from ~~about~~ 500 µg to ~~about~~ 1500 µg per day.
5. The ~~method of C~~use as claimed in claim 1, wherein administration of the composition comprising DA-DKP, is commenced within 24 hours of diagnosis of rhinitis.
6. The ~~method of C~~use as claimed in claim 1, wherein administration of the composition comprising DA-DKP, is commenced at the appearance of one or more early signs of, or a predisposition to develop, rhinitis.
7. The ~~method of C~~use as claimed in claim 6, wherein the one or more early signs of rhinitis are selected from the group consisting of rhinorrhea, nasal congestion, nasal itching and sneezing.
8. The ~~method of C~~use as claimed in claim 1, wherein the DA-DKP is in a composition prepared by removing albumin from a solution of a human serum albumin composition.
9. The ~~method of C~~use as claimed in claim 8, wherein the step of removing the albumin comprises treating the human serum albumin composition by a separation method selected from the group consisting of ultrafiltration, sucrose gradient centrifugation, chromatography, salt precipitation, and sonication.
10. The ~~method of C~~use as claimed in claim 9, wherein the step of removing comprises passing the human serum albumin composition over an ~~ultarfiltration~~ ultrafiltration membrane with a molecular weight cut off that retains the albumin, and wherein the resulting filtrate comprises DA-DKP.
11. The ~~method of C~~use as claimed in claim 10, wherein the ultrafiltration membrane has molecular weight cutoff of less than 50 kDa, less than 40 kDa, less than 30 kDA, less than 20 kDa, less than 10 kDa, less than 5 kDa or less than 3 kDA.
12. The ~~method of C~~use as claimed in claim 1, wherein the composition comprising DA-DKP is administered in combination with a second drug suitable for treating rhinitis.

13. The ~~method of C~~use as claimed in claim 12, wherein the second drug suitable for treating rhinitis is selected from the group consisting of antihistamines, decongestants, anti-inflammatories, mast cell stabilizers, leukotriene modifiers and IgE blockers.
14. A pharmaceutical product, comprising a DA-DKP containing composition formulated for ~~administration by a route selected from the group consisting of inhalation, insufflation and~~ nasal administration to the nose in a form of drops or sprays, wherein the DA-DKP comprises from 0.1% (w/v) to 10% (w/v) of the composition.
15. The pharmaceutical product of ~~Claim~~ claim 14, wherein the DA-DKP containing composition is formulated for administration by inhalation is packaged in a device selected from the group consisting of insufflators, nebulizers, pressurized packs, squeeze bottle, a syringe, a dropper, a spray device, an atomizer device, and an aerosolizer.
16. The pharmaceutical product of ~~Claim~~ claim 15, wherein the pressurized pack comprises a propellant selected from the group consisting of dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, and carbon dioxide.

~~17. The pharmaceutical product of Claim 14, wherein the DA-DKP containing composition formulated for administration by inhalation or insufflation comprises a powder mix of the DA-DKP containing composition and a powder base.~~

~~18. The pharmaceutical product of Claim 17, wherein the powder mix is in a dosage form selected from the group consisting of capsules, cartridges, gelatin packs and blister packs.~~

~~19. The pharmaceutical product of Claim 18, wherein the powder mix is delivered by a device selected from the group consisting of an inhalator, insufflator and metered-dose inhaler.~~

~~20. The pharmaceutical product of Claim 14, wherein the DA-DKP containing composition formulated for nasal administration is in a form of drops or sprays.~~

~~21. The pharmaceutical product of Claim 20, wherein the DA-DKP comprises from about 0.1% (w/v) to about 10% (w/v) of the composition.~~

~~22.~~17. The pharmaceutical product of ~~Claim~~ claim ~~20~~14, wherein the drops or sprays are contained within an intranasal delivery system.

~~23.~~18. The pharmaceutical product of ~~Claim~~ claim ~~22~~17, wherein the intranasal delivery system comprises an atomizing device.

~~24.~~19. The pharmaceutical product of ~~Claim~~ claim ~~23~~18, wherein the atomizing device comprises a bottle and a pump.

~~25.~~20. The pharmaceutical product of ~~Claim~~ claim ~~24~~19, wherein the pump is a metered dose pump.

~~26.~~21. The pharmaceutical product of ~~Claim~~ claim ~~25~~20, wherein the metered dose pump delivers an intranasal volume of the DA-DKP containing composition of about 0.15 ml per pump.

~~27.~~22. The pharmaceutical product of ~~Claim~~ claim ~~20~~14, further comprising an aqueous or non-aqueous base comprising one or more agents selected from the group consisting of dispersing agents, solubilizing agents, and suspending agents.

~~28. The pharmaceutical product of Claim 14, wherein the DA-DKP containing composition formulated for nasal administration is in a form selected from the group consisting of ointments, gels and creams.~~

~~29.~~23. The pharmaceutical product of ~~Claim~~ claim ~~28~~14, wherein the DA-DKP containing composition further comprises excipients selected from the group consisting of animal fats, vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicones, bentonites, silicic acid, talc, zinc oxide and mixtures thereof.

~~30.~~24. The pharmaceutical product of ~~Claim~~ claim 14, further comprising an absorption or permeation enhancer.

~~31.~~25. The pharmaceutical product of ~~Claim~~ claim 14, further comprising a thickening agent or viscosity enhancer to increase the residence time of the DA-DKP containing composition in the nose.

~~32.~~26. The pharmaceutical product of ~~Claim~~ claim 14, further comprising a pharmaceutically-acceptable carrier.

~~33.~~27. The pharmaceutical product of ~~Claim~~ claim 14, wherein the DA-DKP is prepared by removing albumin from a solution of a human serum albumin composition.

~~34.~~28. The pharmaceutical product of ~~Claim~~ claim ~~33~~27, wherein the step of removing the albumin comprises treating the human serum albumin composition by a separation method selected from the group consisting of ultrafiltration, sucrose gradient centrifugation, chromatography, salt precipitation, and sonication.

~~35.~~29. The pharmaceutical product of ~~Claim~~ claim ~~34~~28, wherein the step of removing comprises passing the human serum albumin composition over an

~~ultarfiltration~~ ultrafiltration membrane with a molecular weight cut off that retains the albumin, and wherein the resulting filtrate comprises DA-DKP.

~~36.~~30. The pharmaceutical product of ~~Claim~~ claim ~~35~~29, wherein the ultrafiltration membrane has molecular weight cutoff of less than 50 kDa, less than 40 kDa, less than 30 kDA, less than 20 kDa, less than 10 kDa, less than 5 kDa or less than 3 kDA.